Introduction {#s1}
============

The plight of people with type 1 diabetes changed dramatically with the introduction of insulin therapy in 1922 ([@B1]). Type 1 diabetes was transformed from a uniformly fatal disease in the preinsulin era, with mortality occurring either acutely from diabetic ketoacidosis or subsequently from inanition owing to a chronic catabolic state, to a chronic degenerative disease. In the first 15 to 20 years of insulin therapy, a host of complications that had never been seen before was discovered in people with long-term diabetes ([@B2]). These complications, affecting the eyes, kidneys, and peripheral nervous system, were collectively called microvascular complications, to distinguish them from the less diabetes-specific but highly prevalent macrovascular disease complications. Microvascular disease and peripheral neuropathy resulted in blindness, kidney failure, and amputations ([@B3]); and macrovascular disease, exacerbated by renal dysfunction and autonomic neuropathy, increased the risk for myocardial infarctions and stroke to levels that were 10-fold or more than in the age-matched nondiabetic population ([@B2],[@B3]).

The pathoetiology of the microvascular complications was vigorously debated during the mid-20th century ([@B4]--[@B6]). Some practitioners considered the complications a result of nonphysiologically controlled hyperglycemia; others thought that they were a glycemia-independent feature of diabetes. Perhaps the most sensible opinion regarding the role of glucose control, expressed by R.D. Lawrence, the preeminent diabetologist of his time and who had type 1 diabetes himself, was as follows: "The attempt to keep the blood sugar constantly normal may be ideal in theory, but in practice it is very difficult to achieve and makes the diabetic life unnecessarily hard without adequate benefit" ([@B7]).

The devastating consequences of the long-term complications led in part to the formation of the National Diabetes Commission by an Act of Congress (PL 93-354). In 1975, the Commission issued *The Long-Range Plan to Combat Diabetes*, which included the recommendation for the National Institutes of Health (NIH) to "initiate and support a 5-year clinical study to assess the effects of treatment of juvenile-onset diabetes on the development of microvascular and macrovascular complications."

The advances necessary to perform a definitive clinical trial were finally in place by the early 1980s. These included: the ability to manage glucose levels in the near-normal range using multiple daily injection (MDI) therapy or continuous subcutaneous insulin infusion (CSII) with external pumps, guided by self-monitoring of blood glucose (SMBG); the means of measuring chronic glycemia objectively and accurately with the glycated hemoglobin (HbA~1c~) assay; and objective measures of long-term complications. With these tools available and with generous support from the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, which later became the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 21 centers were selected in 1982 to plan and conduct a study that would test what had become known as the "glucose hypothesis." Practically stated, the glucose hypothesis posited that achieving near-normal glucose would ameliorate the long-term complications of diabetes. Over the course of more than a year, the investigators planned the Diabetes Control and Complications Trial (DCCT) ([@B8]). The two primary aims of the DCCT consensus protocol were to determine whether, compared with conventional therapy (CON), an intensive treatment program designed to achieve glycemic control as close to the nondiabetic range as safely possible would prevent or delay the *appearance* of early background retinopathy (primary prevention) and would prevent the *progression* of early retinopathy to more advanced forms of retinopathy (secondary intervention).

After the successful completion of a 1-year feasibility phase, during which a substantial separation of HbA~1c~ levels between the intensive therapy (INT) ("experimental") and CON ("standard") groups was achieved ([@B9]), an additional eight centers were added, and full-scale recruitment began. Recruitment ended in 1989, and the DCCT was halted by its independent oversight committee in 1993, approximately 1 year ahead of schedule, owing to the uniform and conclusive results achieved ([@B10]). The original CON group was taught INT, and the entire cohort was invited to join a long-term observational study named the Epidemiology of Diabetes Interventions and Complications (EDIC) ([@B11]). EDIC is now in its 20th year.

Research Design and Methods {#s2}
===========================

The eligibility criteria have been described in detail ([@B8],[@B10]). Briefly, in order to address the primary prevention and secondary intervention questions, the following eligibility criteria were used: age 13--39 years with type 1 diabetes diagnosed based on clinically accepted criteria and with fasting c-peptide concentrations \<0.2 nmol/L. The subjects had to be generally healthy with no history of cardiovascular disease (CVD) and without hypertension (blood pressure \<140/90 mmHg) or dyslipidemia ([@B8]), and those with neuropathy requiring treatment were excluded. Additionally, the primary prevention cohort had to have a duration of 1--5 years with no evidence of retinopathy on fundus photography and an albumin excretion rate (AER) \<40 mg per 24 h. The secondary intervention cohort could have a longer duration of diabetes (1--15 years) and had to have at least one microaneurysm in either eye. This cohort could have an AER as high as 200 mg per 24 h. Subjects in the primary prevention cohort and those in the secondary intervention cohort with \<5 years duration could have 2-h stimulated c-peptide levels as high as 0.5 nmol/L; otherwise, it had to be ≤0.2 nmol/L.

DCCT Interventions and Metabolic Goals {#s3}
--------------------------------------

The clinical goals for both treatment groups included absence of frequent symptoms of hyperglycemia or frequent or severe hypoglycemia, defined as requiring assistance from another person. DCCT INT aimed to achieve HbA~1c~ levels that were \<2 SD above the mean value determined for similarly aged nondiabetic volunteers (\<6.05%, 42.6 mmol/mol). HbA~1c~ was measured monthly to aid adjustment of INT and quarterly as a process outcome in both therapy groups. Only the quarterly results were used for study data. INT was adjusted based on four or more SMBG tests with the following self-monitored glucose targets: premeals 70--120 mg/dL (3.9--6.7 mmol/L) and 2-h postmeals \<180 mg/dL (10 mmol/L). In addition, a weekly 3:00 [a.m.]{.smallcaps} blood glucose was to be \>65 mg/dL (3.6 mmol/L) in order to protect against otherwise unappreciated nocturnal hypoglycemia. To achieve the glycemic goals, participants randomly assigned to INT used at least three insulin injections per day (MDI) or CSII. The subjects and DCCT clinic staff chose which modality to use. The insulins used were those that were available at the time: clear zinc (regular) insulin for premeal boluses and in the insulin pump and NPH, lente, and beef ultralente insulin for basal delivery in MDI regimens. There was no single MDI or CSII regimen, and clinic staff and participants worked together to individualize the regimens to match lifestyle factors and achieve the SMBG and HbA~1c~ goals ([@B12]).

CON was consistent with standard care in the 1980s and usually included one or two daily injections of insulin with daily urine or SMBG. The only numeric glycemic target was if HbA~1c~ exceeded 13.5%, the mean +2 SD of the cohort's baseline value, in which case treatment was intensified independent of whether the subject had symptoms.

Outcomes {#s4}
--------

Retinopathy, which was measured objectively with stereoscopic fundus photography and graded with standardized methods by a central reading center ([@B13]), was the primary outcome used for power and sample-size calculations. Similarly important outcomes were nephropathy and retinopathy. The measurements and their frequency and definitions of outcomes are included in [Table 1](#T1){ref-type="table"}.

###### 

Major outcome measurements
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EDIC Design and Outcomes {#s5}
------------------------

In the wake of the successful completion of the DCCT ([@B10]), the DCCT investigators and the NIDDK decided that longer-term follow-up would provide important information regarding the durability of the original DCCT INT effects and, in particular, the effects of INT on the more-advanced stages of complications and CVD ([@B11]). After the end of the DCCT and before initiating the long-term follow-up called EDIC, all of the CON participants were offered training in INT. In addition, diabetes care was returned to the subjects' own care provider, some of whom were DCCT/EDIC investigators.

Whereas the DCCT was a controlled clinical trial, EDIC was observational. The frequency of interactions with the subjects and of the outcome measurements decreased substantially ([Table 1](#T1){ref-type="table"}); however, the methods of measuring glycemia, other metabolic outcomes, and complications remained identical to those used during DCCT. Several procedures were added to measure atherosclerosis ([Table 1](#T1){ref-type="table"}).

Results {#s6}
=======

Subjects {#s7}
--------

The characteristics of the DCCT cohort at baseline and at study end, which represents the EDIC baseline, and at the most recent EDIC annual examination in 2012 are shown in [Table 2](#T2){ref-type="table"}. The baseline characteristics were well matched between the INT and CON for the primary prevention and secondary intervention cohorts. The changes over time largely reflect the effects of INT versus CON. Although in most long-term studies loss to follow-up may compromise the integrity and interpretation of study results, the follow-up in DCCT and subsequently in EDIC has been virtually complete. At the end of DCCT, after an average of 6.5 years (range 3--9), more than 99% (1,422 of 1,441) completed the study. After another 20 years of follow-up in EDIC, 88% of the original cohort (95% of the survivors) is being actively followed in DCCT/EDIC clinical centers.

###### 

Clinical characteristics of DCCT/EDIC participants at DCCT baseline, DCCT closeout, and EDIC year 18

![](9tbl2)

Glycemia {#s8}
--------

The DCCT INT did not uniformly achieve the goal HbA~1c~ of \<6.05%; however, 44% reached that level at least once during the trial ([@B10]). The median of the quarterly measured HbA~1c~ levels in INT was 7% compared with 9% in CON ([Fig. 1](#F1){ref-type="fig"}). There was almost no crossover between INT and CON during the DCCT, other than the protocol-dictated change to INT for women assigned to CON who were planning pregnancy and during pregnancy ([@B14]). 97% of study time was spent on assigned therapy. During EDIC, the adoption of INT by the original CON group and the transition for all subjects to their own health care providers resulted in a narrowing and then disappearance of the differences in HbA~1c~ maintained during DCCT ([Fig. 1](#F1){ref-type="fig"}).

![Median HbA~1c~ concentrations during DCCT, the "training" period between DCCT and EDIC, and EDIC. *P* \< 0.001 for INT vs. CON during entire DCCT and for the first 3 years during EDIC. Reprinted and modified with permission from Nathan et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes 2013;62:3976--3986.](9fig1){#F1}

Adverse Effects {#s9}
---------------

The two major adverse events experienced by INT subjects were hypoglycemia and weight gain ([@B15]--[@B17]). The definition established for severe hypoglycemia, which has subsequently been adopted by many studies, was meant to be relatively inclusive but not to include episodes that were recognized and treated by the patients. To qualify as severe hypoglycemia, an episode had to require assistance from another and included coma or seizures or episodes requiring glucagon, IV dextrose, or oral carbohydrate administered by another person. Although the intent was to limit bias of ascertainment by collecting the hypoglycemia events at quarterly visits for both INT and CON subjects, INT subjects were seen and contacted more frequently than those in the CON group, and some of the differences in hypoglycemia may be attributable to differences in the frequency of ascertainment. The frequency of severe hypoglycemia (62/100 patient-years) and the subset of episodes involving coma or seizure (16/100 patient-years) were both threefold higher than in the CON group. Despite the increased frequency of hypoglycemia, there were no adverse effects of INT or of repeated severe episodes, on rigorously and repeatedly measured cognitive function in adults or adolescents, either during the DCCT or after even longer-term follow-up ([@B18]--[@B20]). Weight gain with INT resulted in significantly more subjects becoming overweight or obese compared with CON ([@B17]). The 4.6 kg difference in weight during the DCCT largely dissipated during the EDIC.

Outcomes {#s10}
--------

More detailed descriptions of the individual outcomes are presented in the subsequent articles in this series ([@B21]--[@B25]). In brief, DCCT INT reduced the early stages of microvascular complications by 35--76% compared with CON ([Fig. 2](#F2){ref-type="fig"}) ([@B10]). The magnitude and consistent direction of the effects on retinopathy, neuropathy, and nephropathy led to the termination of the study 1 year ahead of schedule by the independent oversight group. Analyses of the relationship between metabolic control, measured by the "updated mean" HbA~1c~ and including approximately 18,000 HbA~1c~ measurements for each therapy group, revealed a strong association with each of the three complications ([@B26],[@B27]). The difference in updated mean HbA~1c~ levels between the therapy groups explained the vast majority (\>98%) of the difference in complications between the groups ([@B26]), leaving little room for other established or putative risk factors to play a role in the trial's differential outcomes.

![Summary of reduction in major complications with INT compared with CON during DCCT, EDIC, and combined study periods. 3+step devel, Prim: three-step or more development of retinopathy based on Early Treatment of Diabetic Retinopathy scale (ref. [@B13]) in the primary prevention group. Scnd: secondary intervention group. Microalb: microalbuminuria defined as albumin excretion ≥40 mg/24 h. Macroalb: macroalbuminuria defined as albumin excretion \>300 mg/24 h. Reduced GFR: estimated GFR \<60 mL/min/1.73 m^2^. CVD events: CVD including myocardial infarctions, stroke, and CVD death. Reprinted with permission from Nathan et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes 2013;62:3976--3986.](9fig2){#F2}

EDIC/Metabolic Memory {#s11}
---------------------

Considering the powerful effect that glycemic separation had on the outcomes during DCCT, the subsequent narrowing and then disappearance of the difference in HbA~1c~ levels between the two original therapy groups during EDIC could logically have been expected to result in the subsequent parallel development of complications. However, the first 4 years of the EDIC follow-up demonstrated a further widening of the differences in outcomes, after adjusting for EDIC baseline outcomes ([@B28]). This phenomenon of a durable effect on complications of prior metabolic control was named "metabolic memory." It affects all of the microvascular complications ([@B29]--[@B32]). Studies during EDIC suggested that glycation of long-lived proteins, such as dermal collagen, might account for this persistent effect ([@B33]). Regardless of the mechanism, metabolic memory has lasted for at least 10 years.

The long-term EDIC follow-up has allowed the study of the impact of INT versus CON on more advanced complications than were studied during the DCCT. Major beneficial effects of INT on advanced complications ([@B34]), including retinopathy ([@B35]), nephropathy (reduced glomerular filtration rate \[GFR\]) ([@B36]), and autonomic manifestations of neuropathy ([@B37]), have been demonstrated ([Fig. 2](#F2){ref-type="fig"}). Finally, measurements of atherosclerosis in several macrovascular beds, including carotid intima media thickness ([@B38]) and computed tomography--measured coronary artery calcification ([@B39]), have revealed less atherosclerosis in the INT group. The clinical expression of these changes, fatal and nonfatal myocardial infarctions and stroke, were also reduced by INT, with a 58% reduction in CVD events after a mean of 18 years of follow-up from the beginning of the DCCT ([@B40]).

Conclusions {#s12}
===========

The DCCT and its observational EDIC follow-up were designed to determine whether the long-term complications that affect people with type 1 diabetes could be ameliorated by intensive glycemic therapy. The DCCT/EDIC convincingly demonstrated that the glucose hypothesis was correct and that an intervention that aimed to achieve glycemia as close to the nondiabetic range as safely possible reduced all of the microvascular and cardiovascular complications of diabetes. Translating the findings of the DCCT/EDIC into clinical care has substantially improved the long-term health of people with type 1 diabetes.

Clinical trial reg. nos. NCT00360815 and NCT00360893, [clinicaltrials.gov](http://clinicaltrials.gov).

\*A complete list of participants in the DCCT/EDIC Research Group can be found in N Engl J Med 2011;365:2366--2376.

See accompanying articles, pp. 5, 8, 17, 24, 31, 39, and 44.
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